EL SEGUNDO, Calif. — Gov. Gavin Newsom announced Thursday that CalRx biosimilar insulin glargine pens will be available to consumers in California beginning Jan. 1, 2026. The launch comes amid the ...
SACRAMENTO, CA – Setting a national precedent, California will sell its own state-branded insulin, making life-saving diabetes medication affordable for millions. Governor Gavin Newsom announced that ...
SEA COAST ROADS 95 101 GREEN IN BOTH DIRECTIONS. SENATOR JEANNE SHAHEEN IS LEADING AN EFFORT IN CONGRESS TRYING TO KEEP INSULIN COSTS LOW. THIS MORNING, THE SENATOR HOSTING A ROUNDTABLE DISCUSSION AT ...
Langlara is supplied as a 3mL single-patient-use prefilled pen. The Food and Drug Administration (FDA) has approved Langlara ™ (insulin glargine-aldy), an interchangeable biosimilar to Lantus ® ...
The FDA has approved Langlara, an interchangeable biosimilar to Lantus. The interchangeability designation allows pharmacists to substitute Langlara for Lantus without prescriber intervention in ...
Credit: Lannett. The approval was based on a comprehensive clinical program that included a phase 1 study comparing insulin glargine-aldy with insulin glargine in healthy male adults. Langlara is ...
PHILADELPHIA--(BUSINESS WIRE)--Lannett Company, Inc., Lanexa Biologics, a wholly owned subsidiary of Lannett, and Sunshine Lake Pharma today announced that the U.S. Food and Drug Administration (FDA) ...
Lannett Company, Inc., Lanexa Biologics, a wholly owned subsidiary of Lannett, and Sunshine Lake Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved LANGLARA™ (insulin ...
This Interchangeable Biosimilar Insulin Glargine Approved for U.S. Distribution Through Newly Established Subsidiary Lanexa Biologics LLC Lannett Company, Inc., Lanexa Biologics, a wholly owned ...
A bipartisan quartet of of senators on Wednesday unveiled legislation to cap the monthly cost of insulin at $35 for patients on private insurance. Sens. Jeanne Shaheen (D-N.H.), Susan Collins (R-Maine ...
A bipartisan group of senators is resurfacing legislation to cap many American patients’ insulin costs at $35 a month — the INSULIN Act of 2026 — reviving a push that previously stalled. The bill, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results